Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study

Diabetes and Vascular Disease Research

Volumn 13, Issue 3, 2016, Pages 236-243

  Leung, Melissa ^a   Leung, Dominic Y ^a   Wong, Vincent W ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

Author keywords

cardiac function; diabetes mellitus; Dipeptidyl peptidase 4 inhibition; endothelial function

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; LIPID; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; AGED; BLOOD; BRACHIAL ARTERY; CONVALESCENCE; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; HEART CONTRACTION; HYPEREMIA; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; BIOMARKERS; BLOOD GLUCOSE; BRACHIAL ARTERY; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PILOT PROJECTS; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 84964402831     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164116629352     Document Type: Article

References (30)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
2. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 1974; 23: 105-111.
3. Zabalgoitia M, Ismaeil MF, Anderson L, et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001; 87: 320-323.
4. Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110: 826-833.
5. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14: 561-567.
6. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012; 29: 14-25.
7. Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2012; 77: 1337-1344.
8. Chinda K, Sanit J, Chattipakorn S, et al. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart. Diab Vasc Dis Res 2014; 11: 75-83.
9. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3: 195-201.
10. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 592760.
11. Picatoste B, Ramirez E, Caro-Vadillo A, et al. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLOS ONE 2013; 8: e78330.
12. Nogueira KC, Furtado M, Fukui RT, et al. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-a pilot study. Diabetol Metab Syndr 2014; 6: 103.
13. Ussher JR, Drucker DJ,. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
14. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
15. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
16. Standl E, Erbach M, Schnell O,. Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 2014; 16: 353.
17. Ng AC, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2009; 104: 1398-1401.
18. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.
19. Royal Australian College of General Practitioners and Diabetes Australia. General practice management of type 2 diabetes: 2015, https://www.diabetesaustralia.com.au/best-practice-guidelines
20. Stenton C,. The MRC breathlessness scale. Occup Med 2008; 58: 226-227.
21. Leung M, Juergens CP, Lo ST, et al. Evaluation of coronary microvascular function by left ventricular contractile reserve with low-dose dobutamine echocardiography. EuroIntervention 2014; 9: 1202-1209.
22. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery-a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
23. Leung M, Phan V, Leung DY,. Endothelial function and left ventricular diastolic functional reserve in type 2 diabetes mellitus. Open Heart 2014; 1: e000113.
24. Fadini GP, Avogaro A,. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011; 55: 10-16.
25. Hamdani N, Hervent AS, Vandekerckhove L, et al. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc Res 2014; 104: 423-431.
26. Clifton P,. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clin Ther 2014; 36: 2072-2079.
27. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242.
28. Fang ZY, Prins JB, Marwick TH,. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-567.
29. Joshi M, Kotha SR, Malireddy S, et al. Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. Mol Cell Biochem 2014; 386: 233-249.
30. Mason RP, Jacob RF, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol 2012; 60: 467-473.